Recent advances in microtubule-stabilizing agents

YN Cao, LL Zheng, D Wang, XX Liang, F Gao… - European journal of …, 2018 - Elsevier
Highly dynamic mitotic spindle microtubules are superb therapeutic targets for a group of
chemically diverse and clinically successful anticancer drugs. Microtubule-targeted drugs …

Recent progress with microtubule stabilizers: new compounds, binding modes and cellular activities

CC Rohena, SL Mooberry - Natural product reports, 2014 - pubs.rsc.org
Covering: late 2008 to August 2013 Nature has yielded numerous classes of chemically
distinct microtubule stabilizers. Several of these, including paclitaxel (Taxol) and docetaxel …

The binding sites of microtubule-stabilizing agents

JJ Field, JF Díaz, JH Miller - Chemistry & biology, 2013 - cell.com
Microtubules (MTs) are a highly successful target for anticancer therapy. MT-stabilizing
agents (MSAs) bind to MTs, promoting their polymerization, blocking mitosis, and causing …

Mitosis, Cytoskeleton Regulation, and Drug Resistance in Receptor Triple Negative Breast Cancer

A Matov - arxiv preprint arxiv:2407.19112, 2024 - arxiv.org
During cell division, the receptor triple-negative MDA-MB-231 mitotic spindles are the
largest in comparison to other BC cell lines. Many of the MDA-MB-231 spindles exhibit rapid …

Mechanisms of tubulin binding ligands to target cancer cells: updates on their therapeutic potential and clinical trials

B Kumar, R Kumar, I Skvortsova… - Current cancer drug …, 2017 - ingentaconnect.com
Background: A number of chemically diverse substances bind to the tubulin and inhibit cell
proliferation by disrupting microtubule dynamics. There are four binding sites for the ligands …

Marine invertebrate natural products that target microtubules

JH Miller, JJ Field, A Kanakkanthara… - Journal of natural …, 2018 - ACS Publications
Marine natural products as secondary metabolites are a potential major source of new drugs
for treating disease. In some cases, cytotoxic marine metabolites target the microtubules of …

Peloruside A: A lead non-taxoid-site microtubule-stabilizing agent with potential activity against cancer, neurodegeneration, and autoimmune disease

A Kanakkanthara, PT Northcote, JH Miller - Natural product reports, 2016 - pubs.rsc.org
Covering: 2000 up to 2016 Peloruside A, a macrocyclic secondary metabolite from a New
Zealand marine sponge, Mycale hentscheli, has shown potent antiproliferative activity in …

Modulation of the Cytoskeleton for Cancer Therapy

A Matov - Available at SSRN 5061950, 2024 - papers.ssrn.com
Introduction: All degenerative diseases are associated with impairment in intracellular
trafficking. The highly dynamic organization and remodeling of the cellular cytoskeleton are …

Clinical development of anti-mitotic drugs in cancer

AM Olziersky, SI Labidi-Galy - Cell Division Machinery and Disease, 2017 - Springer
Mitosis is one of the most fundamental processes of life by which a mammalian cell divides
into two daughter cells. Mitosis has been an attractive target for anticancer therapies since …

F240 of β2-Tubulin Explains why Fusarium graminearum is Less Sensitive to Carbendazim than Botrytis cinerea

Y Zhu, X Liang, Y Li, Y Duan, Z Zheng… - …, 2018 - Am Phytopath Society
β-Tubulin is the target of benzimidazole fungicides, the most widely used of which is
carbendazim (methyl benzimidazol-2-ylcarbamate [MBC]). MBC sensitivity is determined by …